Epstein Secrets

Takeaways from FOURIER "We've never been able to plumb these depths before." lead author Marc S. Sabatine, MD, of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. "These data strongly suggest that patients benefit from lowering LDL cholesterol well below current targets."

esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright C' 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communicatio

L to lowest, 74 mg/dL). 'We've never been able to plumb these depths before," lead author Marc S. Sabatine, MD, of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. "These data strongly suggest that patients benefit from lowering LDL cholesterol well below current targets."

esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright @ 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communication

owest, 74 mg/dL). IIr 'We've never been able to plumb these depths before," lead author Marc S. Sabatine, MD. of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. -These data strongly suggest that patients benefit from lowering LDL cholesterol well below current targets."

esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright O 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communication